Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Pancreatic Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 19Cyclophosphamide 12Peripheral Blood Stem Cell Transplantation 10Filgrastim 10fludarabine phosphate 9Bortezomib 9Radiotherapy 8Cyclosporine 8tanespimycin 6Prednisone 6Magnetic Resonance Spectroscopy 6Etoposide 6Vorinostat 5Vincristine 5Lenalidomide 5Indium 5Ifosfamide 5temsirolimus 4bryostatin 1 4alvocidib 4Paclitaxel 4Interferon-alpha 4Gemcitabine 4Doxorubicin 4Cytarabine 4Busulfan 4sargramostim 3ibrutinib 3apolizumab 3aldesleukin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, B-Cell, Marginal Zone × Antibodies, Monoclonal × Clear all
NCT00265928 2008-01-28

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
46 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡